Dr. Nooka is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1365C Clifton Rd NE
Atlanta, GA 30322Phone+1 404-778-0655Fax+1 404-778-5530
Education & Training
Emory University School of MedicineFellowship, Hematology and Medical Oncology, 2008 - 2011
Canton Medical Education Foundation/NEOMEDResidency, Internal Medicine, 2005 - 2008
Andhra Medical College NTRClass of 2000
Certifications & Licensure
GA State Medical License 2009 - 2025
OH State Medical License 2005 - 2008- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Phase 1/2a Study of Cancer Vaccine to Treat Smoldering Multiple Myeloma Start of enrollment: 2012 Nov 01
- Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Relapsed/Refractory Multiple Myeloma Start of enrollment: 2014 Jun 30
- A Phase 1 Study Evaluating CB-5083 in Subjects With Lymphoid Hematological Malignancies Start of enrollment: 2014 Aug 25
- Join now to see all
Publications & Presentations
PubMed
- Heme promotes venetoclax resistance in multiple myeloma through MEK-ERK signaling and purine biosynthesis.Remya Nair, An Vu, Abigail K Freer, Karanpreet S Bhatia, Dongxue Wang
Blood. 2024-12-18 - 4 citationsIde-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses.Sikander Ailawadhi, Bertrand Arnulf, Krina Patel, Michele Cavo, Ajay K Nooka
Blood. 2024-12-05 - 1 citationsEfficacy and safety of teclistamab in patients with relapsed/refractory multiple myeloma after BCMA-targeting therapies.Cyrille Touzeau, Amrita Y Krishnan, Philippe Moreau, Aurore Perrot, Saad Z Usmani
Blood. 2024-12-05
Abstracts/Posters
- Comprehensive Investigation of White Blood Cell and Gene Expression Profiles As Risk Factors for Multiple Myeloma in African AmericansAjay K Nooka, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Efficacy and Safety of Daratumumab, Bortezomib, and Dexamethasone (D-Vd) Versus Bortezomib and Dexamethasone (Vd) in First Relapse Patients (pts) with Multiple Myeloma...Ajay K Nooka, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrang...Ajay K Nooka, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Join now to see all
Lectures
- Influence of Cytogenetics in Patients with Relapsed Refractory Multiple Myeloma Treated with Oral Selinexor and Dexamethasone: A Post-Hoc Analysis of the STORM Study61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Outcomes of Myeloma Patients with Deletion 1p Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD) Therapy2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Evaluation of All Cause of Death after High Dose Chemotherapy and Autologous Stem Cell Transplant in Hodgkin Lymphoma and Non-Hodgkin Lymphoma2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Join now to see all
Press Mentions
International Myeloma Foundation Medical Student Scholars for Health Equity in Myeloma Present Posters at the 2024 NMA Annual Convention & Scientific AssemblyAugust 15th, 2024- Research Roundup: Recent Grants and Publications for Emory Faculty and StaffSeptember 6th, 2022
- The ‘New World’ of Multiple Myeloma TreatmentApril 26th, 2022
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
